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168Objective: We aimed to evaluate the influence of size disparity of the transplanted heart on cardiac growth in
infant and child recipients by comparing donor body surface area (BSA) and cardiac dimensions during trans-
plantation to the corresponding parameters of the recipient over a period of time.
Methods: A retrospective review of medical and echocardiographic records of 147 children (5.3 4.0; median,
4.1; range, 1 month–15 years) who underwent orthotopic heart transplantation was done. The patients were di-
vided into age groups as follows: less than 1 year (n¼ 23), 1 to 2 years (n¼ 26), more than 2 to 5 years (n¼ 18),
more than 5 to 10 years (n ¼ 27), and more than 10 to 15 years (n ¼ 53). Donor/recipient BSA ratio was de-
termined during transplantation. Cardiac dimensions were measured 30 days after transplantation and compared
at 1 year, 2 to 5 years, and 5 to 10 years after transplantation.
Results: There were no significant differences in the ventricular end-diastolic diameter, volumes, and mass
among those with a donor/recipient BSA ratio of less than 0.80, 0.8 to 1.2, and more than 1.2 (P ¼ .80, .44,
and .48, respectively). In all the cardiac dimensions and volumes measured, donor–recipient mismatch did
not influence the continuous growth of the heart, as indicated by the measured parameters, in accordance
with the recipients’ increase in BSA over time. All calculated Z-scores at 1 year, 2 to 5 years, and 6 to 10 years
after transplantation were normal when indexed to BSA.
Conclusions: This study demonstrates that despite size disparity of a transplanted heart, it undergoes normal
growth in diastolic dimensions, volumes, and myocardial mass over time as appropriate for body growth after
cardiac transplantation in infants and children. (J Thorac Cardiovasc Surg 2012;143:168-77)Great advances have been made in the field of pediatric
heart transplantation since the first unsuccessful effort
in a 17-day-old child with a severe form of Ebstein anom-
aly by Kantrowitz and associates1 in Brooklyn, New
York, in December 1967, the first human heart transplant
in the United States. This attempt showed the feasibility
of heart transplantation in children and it is now widely
accepted as a treatment modality for infants and children
with end-stage cardiomyopathy or noncorrectable con-
genital heart diseases.2-4 Several previous investi-
gations5-9 in recent years have focused on the long-term
function of the transplanted heart. However, there is
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The Journal of Thoracic and Cardiovascular Surgdevelopment of the transplanted heart in infants and chil-
dren, as well as data addressing heart remodeling after
transplantation. Previous studies8-11 demonstrated that
after pediatric cardiac transplantation, cardiac chamber
growth is normal over the long-term period, but few publi-
cations12,13 have focused on ventricular growth in children
after cardiac transplantation, and the patterns of changes in
cardiac dimensions after transplantation have remained
unclear.12 This issue is especially important inasmuch as
the elucidation of changes inventricular dimensions and vol-
umes during this periodwould improve our understanding of
the process of adaptation of the donor heart to the recipient’s
circulation, especially after donor–recipient size disparity
transplantation. Several studies14-17 have focused on the
impact of donor/recipient weight ratio on survival and late
outcome after pediatric heart transplantation. Presently,
there is no known long-term study available regarding the
impact of size disparity of the transplanted heart on cardiac
growth in infants and children over time.
We therefore aimed to evaluate the influence of donor–re-
cipient size disparity on the growth of the transplanted heart
in infants and children by comparing donor body surface
area (BSA) and cardiac dimensions during transplantation
with the corresponding parameters of the recipient over
a period of time.ery c January 2012
Abbreviations and Acronyms
BSA ¼ body surface area
LV ¼ left ventricular
RV ¼ right ventricular
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XPATIENTS AND METHODS
The Institutional Review Board of Deutsches Herzzentrum Berlin ap-
proved this retrospective study and waived the need for patient consent.
Patients
We studied 147 patients who underwent orthotopic heart transplantation
at the Deutsches Herzzentrum Berlin between 1986 and 2010. Indications
for heart transplantation were cardiomyopathy, myocarditis, or endocardial
fibrosis in 115 patients and congenital heart disease in 32 patients. Medical
records were reviewed for age, gender, weight, height, BSA, and indica-
tions for transplantation. The donor’s age, height, and weight at the time
of transplantation were likewise noted. Patients were reviewed on the basis
of age groups (<1, 1-2,>2-5,>5-10, and>10-15 years old) and on their
donor/recipient BSA ratio (ie,<0.8, 0.8-1.2, and>1.2).
Immunosuppression Protocol
Our triple-drug immunosuppressive therapy consists of an induction
therapy designed to reduce the incidence of early rejection and is given 6
hours after heart transplantation with intravenous antithymocyte globulin
1.5 mg/kg on the first 3 days accompanying intravenous prednisolone at
2.5 to 5 mg $ kg1 $ d1. Thereafter, steroids are tapered at 2 mg $ kg1 $
d1 orally. Cyclosporine is started preoperatively at 6 mg/kg orally and is
continued at 2 mg/kg intravenously or 6 mg/kg orally to target a trough
level of 250 ng/mL. Mycophenolate mofetil is started preoperatively at
1000 mg orally and is continued at 1000 mg twice daily either orally or in-
travenously. This triple therapy with cyclosporine/mycophenolate mofetil/
steroids is alternatively applied with everolimus (23 0.75 mg orally daily,
target trough levels 3-8 ng/mL) instead of mycophenolate mofetil if there
are no contraindications to everolimus.18
Follow-up
No patients were lost to follow-up. Follow-up data with series of echo-
cardiograms of the children who underwent transplantation between 1986
and 2010 were provided by the Department of Congenital Heart Disease/
Pediatric Cardiology and Department of Clinical Studies, Deutsches
Herzzentrum Berlin, and by written correspondence from the referring
physicians. It is our institutional policy that each transplant patient un-
dergo echocardiographic examination on a weekly basis from the first
posttransplant week until 24 weeks after transplant. Thereafter, an echo-
cardiographic follow-up protocol consisting of selected posttransplant
time intervals is followed. The mean duration of follow-up was 13 
0.8 years (range, 5 months–24 years), providing a total of 1157.79
patient-years.
Echocardiographic Evaluation of Cardiac
Dimensions, Mass, and Volume
Echocardiogram reports were analyzed in detail to determine the
changes in cardiac dimensions, mass, and volume over the follow-up pe-
riod. Echocardiographic evaluations were done 30 days, 1 year, 5 years,
10 years, and 15 years after transplantation. Each echocardiogram in-
cluded an evaluation of cardiac anatomy, ventricular function, and di-
mensions by 2-dimensional imaging with pulsed and color Doppler
mapping.The Journal of Thoracic and CaMeasurements
Ventricles were imaged from the parasternal and subxiphoid long and
short axes, as well as the apical 4-chamber view. End-diastolic diameter
was measured in the anteroposterior plane as the maximal diastolic diam-
eter between the septal to posterior wall at the level of the papillary muscle
tips. Posterior wall thickness was measured in diastole between the papil-
lary muscles at the level of the papillarymuscle tips. Ventricular lengthwas
measured in diastole from the midpoint of the mitral valve annulus to the
apical endocardium. Ventricular volume was calculated using the biplane
area–length method19,20 (Volume ¼ 5/6 L 3 A), where L is the left
ventricular (LV) length measured from the midpoint of the mitral valve
annulus to the apical endocardium and A is the planimetered LV short-
axis cross-sectional area. Volumewasmeasured in systole (minimal dimen-
sion) and diastole (maximal dimension). The formula used for calculation
of LV end-diastolic volume (LVEDV) is: LVEDV ¼ LVIDd.3 Ventricular
mass was calculated as 1.04([IVSdLVIDdLVPWTd]),3 where IVSd
is interventricular septal thickness in diastole, LVIDd is LV end-diastolic
minor axis dimension, and PWT is LV posterior wall thickness in diastole.
To adjust for age, body size, and growth-related changes inventricular di-
mensions, linear measurements were indexed to the square root of BSA0.5,
while volumetric and mass measurements were indexed to BSA1.5.21
Statistical Analysis
Data were analyzed with SPSS 16.0 (SPSS, Inc, Chicago, Ill) for Win-
dows software program. Demographic and echocardiographic variables
are expressed as mean  standard deviation and mean  standard error of
the mean, respectively, as well as range, as appropriate. Univariate compar-
isons of mean ventricular diameter, volume, and mass andmean changes in-
dexed to the donor’s BSA with those indexed to the recipient’s BSA at
selected posttransplant time intervals (30 days, 1 year, 2-5 years, and 6-10
years) were compared using theStudent t test. Correlations and linear regres-
sion analyseswith the least squaresmethodwere used to evaluate the relation
between donor/recipient BSA ratios and the measured cardiac parameters.
To facilitate comparison between cardiac dimensions, we computed
Z-values as follows: Z-score 0 (measured value–mean value of normal con-
trols)/standard deviation of normal controls. Comparison of survivals was
performed by the log–rank test. Cumulative survivalwas analyzed according
to Kaplan-Meier estimates with 95% confidence intervals.
Definition of Normal Growth
Normal growth was defined as a lack of Z-score change between follow-
up periods. Failure of growth of any dimension would be detected as a
statistically significant decline in Z-score. To verify that our method of
stratifying data from the normal patient population did not itself introduce
errors, we reanalyzed the raw data from one measurement, the ventricular
end-diastolic diameter, using a second statistical method to determine
Z-score divisions. No effect on our analysis of Z-score changes was found.
RESULTS
Patient Profile
The demographic profile of infants and children who un-
derwent cardiac transplantation is shown in Table 1. Mean
age at transplantation was 5.3  4.0 years (median, 4.1
years; range, 1 month–15 years). Mean donor age was
14.9 8.1 years (range, 1 month–60 years). Mean donor/re-
cipient BSA ratio is 1.6. Age at follow-up is a mean of
15.6  8.49 years (range, 2.9 months–33.9 years).
Linear Growth
Over time, linear growth was normal in these patients.
Five patients were 3 standard deviations below normal atrdiovascular Surgery c Volume 143, Number 1 169
TABLE 1. Demographic profile of heart transplant children
Demography Recipient Donor
No. of patients (M/F) 147 (82/63) 147 (89/58)
Age at heart transplantation (mean  SD, y) 5.3  4.0 y (range, 1 mo–15 y) 14.93  8.11 y (range, 1 mo–60 y)
Age at follow-up (mean  SD, y) 15.6  8.49 y (range, 2.9 mo-33.9 y)
Mean weight at transplantation (mean  SD, kg) 28.1  19.4 (median, 23.5; range, 3.5-67) 48.73  22.9 (median, 32; range, 4-90)
Mean height at transplantation (mean  SD, cm) 123.5 33.5 (median, 132; range, 50-177) 141.09  38.2 (median, 38; range, 74-190)
Mean BSA at transplantation (mean  SD, m2) 1.03  0.49 (median,1.02; range, 0.2-1.5) 1.64  0.52 (median, 1.45; range, 0.2-2.2)
SD, Standard deviation; BSA, body surface area.
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Xearly follow-up but were close to the normal range at late
follow-up. These included 3 infants who showed delayed
linear growth while still receiving steroids and 2 children
on high-dose immunosuppressants because of repeated re-
jection episodes. In these patients with poor linear growth,
cardiac chamber growth occurred and was appropriate for
BSA. Over time, the mean change in BSA was 0.28 
0.03m2 (range, 0.12-0.50m2). By expressing cardiac growth
as a function of BSA, we were able to compensate for those
transplant patients who showed delayed linear growth.
Echocardiographic Data: Cardiac Dimensions
Changes in ventricular diameter, volume, and mass after
transplantation for all patients are detailed in Tables 2 and 3.
Thirty days after transplantation. All patients had ini-
tially higher right ventricular (RV) (mean, 18.3  1.2 cm/
m2 BSA) and LV (mean, 28.1  2.4 cm/m2 BSA) end-
diastolic diameters, RV (mean, 124 .5  2.31 mL/m2
BSA) and LV (mean 110.67  2.7 m2 BSA) end-diastolic
volumes, and RV (mean, 21.9  2.2 g/m2 BSA) and
LV (mean, 53.8  4.3 g/m2 BSA) mass in the first 30
days after heart transplantation when compared with their
BSA (Table 2).
One year after transplantation. Comparing the values
obtained during the first 30 days of transplantation, there
was a significant decrease (P ¼ .00) in RV (mean, 14.8 
1.0 cm/m2 BSA) and LV (mean, 23.8  1.9 cm/m2 BSA)
end-diastolic diameters, RV (mean, 101.7  2.6 mL/m2
BSA) and LV (mean, 92.1  7.4 mL/ m2 BSA) end-
diastolic volumes, and RV (mean, 19.9  1.5 g/m2 BSA)TABLE 2. Echocardiographic data on ventricular diameter, volume, and
Echocardiographic variables
F
30 d Z-score 1 y
RVEDD (cm/m2, BSA), mean  SEM 18.3  1.2 1.9 toþ3.7 14.8 
RVEDV (mL/m2 BSA), mean  SEM 124.5  2.31 2.0 toþ3.9 101.7 
RV myocardial mass (g/m2 BSA),
mean  SEM
21.9  2.2 2.1 toþ4.0 19.9 
LVEDD (cm/m2 BSA), mean  SEM 28.1  2.4 1.9 toþ3.7 23.8 
LVEDV (mL/m2 BSA), mean  SEM 110.6  2.7 2.0 toþ2.9 92.1 
LV myocardial mass (g/m2 BSA),
mean,  SEM
53.8  4.3 2.1 toþ4.2 43.8 
RVEDD, Right ventricular end-diastolic dimension; BSA, body surface area; SEM, standar
ular; LVEDD, left ventricular end-diastolic dimension; LVEDV, left ventricular end-diasto
170 The Journal of Thoracic and Cardiovascular Surgand LV (mean, 43.8  7.4 g/m2 BSA) mass during the first
year after heart transplantation, regardless of the BSA ratio
(Tables 2 and 3). Calculated Z-scores were normal when
indexed to BSA (Table 2).
Two to 5 years after transplantation. Over the follow-up
intervals of 2 to 5 years after transplantation, the ventricular
end-diastolic diameters (RV mean, 21.4  1.6 cm/m2 BSA,
and LV mean, 26.5 3.4 cm/m2 BSA), the ventricular end-
diastolic volumes (RV mean, 109.2 2.7 mL/m2 BSA, and
LV mean, 101.33.9 mL/m2 BSA), and ventricular mass
(RV mean, 27.4  3.9 g/m2 BSA, and LV mean, 67.4 
3.8 g/m2 BSA) increased in accordance with the linear
growth of recipients, regardless of BSA ratio. Comparing
these to the values obtained during the first posttransplanta-
tion year, these were significant increases (P ¼ .00) as well
as when compared with the values obtained 30 days after
transplantation (Tables 2 and 3).
Six to 10 years after transplantation. The ventricular
end-diastolic diameters (RV mean, 27.17  1.1 cm/m2
BSA, and LVmean, 30.9 1.9 cm/m2 BSA), the ventricular
end-diastolic volumes (RV mean, 116.54  5.6 mL/m2
BSA, and LVmean, 108.54 8.0 mL/m2 BSA) and ventric-
ular mass (RVmean, 36.5 2.6 BSA, and LVmean, 79.8
3.2 g/m2 BSA) increased proportionally 6 to 10 years after
heart transplantation in all patients regardless of the BSA
ratio. All echocardiographic parameters attained statisti-
cally significant difference when compared with values
measured at 1 year (P¼ .00) and 2 to 5 years (P¼ .00) after
transplantation (Tables 2 and 3) but were not influenced by
BSA ratio.mass during different follow-up periods
ollow-up, posttransplantation time
Z-score 2-5 y Z-score 6-10 y Z-score
1.0 1.0 toþ1.5 21.4  1.6 1.8 toþ1.6 27.1  1.1 1.9 toþ1.8
2.6 1.3 toþ1.8 109.2  2.7 1.3 toþ1.9 116.5  5.6 1.2 toþ2.3
1.5 1.4 toþ1.7 27.4  3.9 1.8 toþ1.8 36.5  2.6 1.9 toþ2.4
1.9 1.0 toþ1.9 26.5  3.4 1.0 toþ1.9 30.9  1.9 0.9 to 2.0
7.4 1.3 toþ1.8 101.3  3.9 1.3 toþ1.9 108.5  8.0 1.2 toþ2.4
7.4 1.4 toþ1.8 67.4  3.8 1.7 toþ2.1 79.8  3.2 1.8 toþ2.3
d error of the mean; RVEDV, right ventricular end-diastolic volume; RV, right ventric-
lic volume; LV, left ventricular.
ery c January 2012
TABLE 3. Multivariate analysis of ventricular diameter, volume, and
mass during different follow-up periods
Paired sample tests
P valueOR 95% CI
RVEDD (cm/m2 BSA)
1 vs 2 8.352 6.576 to 10.648 .00
1 vs 3 3.258 0.602 to 2.473 .00
1 vs 4 0.560 0.46 to 1.331 .57
RVEDV (mL/m2 BSA)
1 vs 2 6.335 21.796 to 41.537 .00
1 vs 3 4.638 14.979 to 37.222 .00
1 vs 4 2.984 7.871 to 39.063 .00
RV myocardial mass (g/m2 BSA)
1 vs 2 6.565 2.441 to 4.490 .00
1 vs 3 6.389 5.595 to2.295 .00
1 vs 4 14.547 13.53 to10.29 .00
LVEDD (cm/m2 BSA)
1 vs 2 8.957 10.912 to 17.083 .00
1 vs 3 8.581 11.275 to 18.02 .00
1 vs 4 8.156 12.195 to 20.008 .00
LVEDV (mL/m2 BSA)
1 vs 2 5.839 19.073 to 38.564 .00
1 vs 3 4.094 11.93 to 34.19 .00
1 vs 4 2.594 4.541 to 34.073 .11
LV myocardial mass (g/m2 BSA)
1 vs 2 7.311 10.369 to 18.059 .00
1 vs 3 3.429 2.880 to 10.736 .00
1 vs 4 2.71 4.713 to 3.577 .78
Postoperative follow-up: 1 ¼ 30 days; 2 ¼ 1 year; 3 ¼ 2-5 years; 4 ¼ 6-10 years.
OR, Odds ratio; CI, confidence intervals; RVEDD, right ventricular end-diastolic
dimension; BSA, body surface area; RVEDV, right ventricular end-diastolic volume;
RV, right ventricular; LVEDD, left ventricular end-diastolic dimension; LVEDV, left
ventricular end-diastolic volume; LV, left ventricular.
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years after transplantation were normal when indexed to
BSA (Table 2). Ventricular end-systolic and end-diastolic
diameters fell between the 5th and 95th percentiles, and
all patients demonstrated normal chamber growth. Al-
though cardiac mass is linearly related to BSA, cardiac
dimensions increase as an exponential function of BSA.
The cardiac dimensions and volumes measured are dem-
onstrated in Figure 1, A-F. As BSA increases, there is an
associated increase in cardiac dimensions and volume.
The mean ventricular diameters and myocardial mass,
which was 85.6%  16.8% of that predicted normal for
BSA after the first year and 96.4%  7.5% of that pre-
dicted normal after 5 years, suggests growth and adaptation
of cardiac dimensions and volumes appropriate for body
growth.Donor–Recipient Sizes
Because a size mismatch between the donor and recipient
could result in early alterations in the perceived cardiac
growth rate, we compared donor and recipient size byThe Journal of Thoracic and Caa paired Student t test and found no significant differences
among those with a donor/recipient BSA ratio of less than
0.8, 0.8 to 1.2, and more than 1.2 (P ¼ .80, .44, and .48, re-
spectively). Figure 2, A, B, and C, shows the cardiac dimen-
sions stratified on the basis of donor/recipient BSA ratio
over the follow-up period, which were proportionate to
the increase in body growth over the matched follow-up pe-
riod. All recipients experienced normal volume growth
commensurate with BSA growth to maintain a ratio of ven-
tricular volume predicted for BSA of greater than 90%. The
ventricular mass increased in accordance with the increase
in end-diastolic volume.
In all the cardiac dimensions and volumes measured, do-
nor–recipient mismatch did not influence the continuous
growth in the measured parameters according to the recipi-
ents’ BSA over time.
Follow-up and Survival
The mean duration of follow-up was 13  0.8 years
(range, 5 months–24 years), providing a total of 1157.79
patient-years. Cumulative survival at 10 and 15 years is
61.7% and 42.8%  8% (Figure 3, A). When the survival
is stratified on the basis of donor/recipient BSA ratio, sur-
vival is 91.2%  6.3.7%, 82.2%  5.1%, 77.4% 
5.8%, and 63.0% 7.5% at 30 days, 1, 5, and 10 years, re-
spectively, for a donor/recipient BSA ratio of less than 1.0;
in patients with a donor/recipient BSA ratio of 1.0, survival
is 81.3% 9.8% and 67.7% 11.9% at both 30 days and
1 year and at both 5 and 10 years, respectively; in patients
with a donor/recipient weight ratio of more than1.0, sur-
vival is 90.4.0%  3.0%, 86.9%  3.6%, 78.8% 
4.3%, 58.0%  6.4%, and 46.3% 7.4% at 30 days and
1, 5, 10, and 20 years, respectively (Figure 3, B).
There is no statistically significant difference in survivals
among patients with different donor/recipient BSA ratios
(P ¼ .53).
DISCUSSION
The questions of whether a transplanted heart in a new-
born will grow to adult size along with the child, in the pres-
ence of size disparity, and whether the dimensional growth
of the organ allows adequate function over time have been
largely answered in this investigation. The other question
that awaits an answer is what could be the mechanisms in-
volved in the adaptation of a transplanted heart to its new
environment, especially when an adult heart is transplanted
into a child, where the size mismatch is obvious, and we are
focusing on this issue in on-going investigations.
We have shown in this study that cardiac dimensions and
volumes increased in size appropriate to age and BSA of the
recipient over time, regardless of donor–recipient size mis-
match. Over time, even a large transplanted heart adapts to
its new environment accordingly and grows along with the
somatic growth of the recipient.rdiovascular Surgery c Volume 143, Number 1 171
FIGURE 1. A, Right ventricular end-diastolic diameter (RVEDD). B, Left ventricular end-diastolic diameter (LVEDD). C, Right ventricular end-diastolic
volume (RVEDV). D, Left ventricular end-diastolic diameter (LVEDV). E, Right ventricular (RV)myocardial mass. F, Left ventricular (LV)myocardial mass,
over time. BSA, Body surface area.
Cardiothoracic Transplantation Delmo Walter et al
T
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heart to the functional demands of the recipient circulation
in the first months after transplantation in infants and chil-
dren. A large donor heart would be expected to exhibit re-
gression of ventricular mass with time as an adaptive
phenomenon.13 This phenomenon may represent the effect
of intrinsic time-dependent factors that regulate cardiac
growth.22 These factors are unrelated to functional de-
mands of the heart and may involve genetic programming
as well as humoral growth factors, which may persist in
the recipient circulation for a period after transplantation
regardless of the size of the transplanted organ. This could
lead to continued growth of the myocardium in the early172 The Journal of Thoracic and Cardiovascular Surgposttransplant period, manifesting as the early increase
in ventricular mass and volume that we observed regard-
less of donor/recipient BSA ratio. Over time after trans-
plantation, the effect of these intrinsic factors may be
overridden by the effect of load-dependent adaptation of
the heart.
It may be disputed whether our findings represent car-
diac growth of a small heart to increasing cardiac output
requirements and/or physiologic adaptation of a large
transplanted heart. This issue is interesting and provoca-
tive. Our findings may suggest that the younger the patient
is at the time of transplantation, the greater is the magni-
tude of early increase and subsequent decrease inery c January 2012
FIGURE 2. Comparison of ventricular end-diastolic diameter (A), ventricular volume (B), and ventricular mass (C), stratified according to body surface
area (BSA) ratio, over time.
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Xventricular mass with the remodeling process. Significant
decrease in cardiac dimensions, volumes, and mass during
the first posttransplant year clearly showed that the ventri-
cles remodeled, which is in agreement with the findings
of Hirsch and associates.13 This remodeling consisted
primarily of regression of end-diastolic diameters and
volumes and myocardial mass. The trigger initiating
regression is likely to include the load modulation of ven-
tricular mass.23 By 1 year after transplantation, the LV
mass has decreased significantly from the original mass
30 days after transplantation, suggesting that the heart un-
dergoes extensive adaptive changes mediated by pressure
and volume factors. It is likely that neurohumoral factors
and intrinsic myocyte responses to the altered pressure andThe Journal of Thoracic and Cavolume load contribute to these altered hemodynamic
adaptations.
The determinants of myocardial growth have not been
defined. Zak22 demonstrated that differentiation and growth
of the heart are governed by intrinsic or time-dependent
factors, which include myogenesis and cardiac looping
occurring in the absence of hemodynamic influences and
by extrinsic factors related to the cardiac performance re-
sponding to functional demands, such as compensatory hy-
pertrophy that follows an increase in hemodynamic load. As
the body weight doubles by 6 months and triples by 1 year
of age, the cardiac weight increases similarly.24 The fetal
period of myocardial growth is characterized by mitotic di-
vision, and cellular proliferation continues in the earlyrdiovascular Surgery c Volume 143, Number 1 173
FIGURE 3. A, Cumulative survival after orthotopic heart transplantation. B, Survival stratified according to donor/recipient BSA ratio.
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Xpostnatal period with a rapid decline. Further growth is
characterized by an increase in cell diameters. The signal
to cease proliferation is unknown. The potential for prolif-
eration to be restimulated remains an intriguing concept
supported by the work of Chien and associates,25 in which
the activation of cardiac target genes resulted in embryonic
gene expression.
In this study we have demonstrated that, even in the pres-
ence of delayed linear growth, normal cardiac growth
occurs. Because ventricular systolic and end-diastolic di-
mensions may be more dependent on volume loading con-
ditions than on increase in cell size, our long-term results
are confirmative. The restrictive physiologic function ob-
served at 1 month after transplantation normalized over
a period of 1 year, adapting to the recipient circulation.
This suggests that hearts can adapt rapidly to altered pres-
sure and volume loads and show marked remodeling over
time to maintain the circulatory burden.
This evidence shows that the transplanted heart has the
ability to adapt to new hemodynamic burdens, suggesting
that, regardless of the donor/recipient BSA ratio, the trans-
planted hearts could rapidly adapt to the new hemodynamic
environment and that after the immediate posttransplant pe-
riod the transplanted heart could maintain an appropriate
circulation according to the recipient’s circulatory
demands.
From a clinical standpoint, the results of this study indi-
cate that the use of oversized or undersized donor hearts
within a certain range appears to bewell tolerated after heart
transplantation. Our policy in pediatric heart transplantation
is that the donor can be 4 times larger than the recipient but
should not be much smaller so as to sustain the immediate
posttransplant hemodynamics. Tang and colleagues14
reported that the use of smaller allografts does not affect174 The Journal of Thoracic and Cardiovascular Surgrecipients’ short- and long-term survival, and smaller allo-
grafts could therefore be accepted in pediatric heart trans-
plantation. Patel and associates15 reported that weight
ratio did not predict mortality after heart transplantation
after controlling for known risk factors, propensity score
adjustment, and matching. Fullerton and coworkers16 also
reported that large size mismatches appear to be well toler-
ated in pediatric heart transplantation.
These observations do not support the contention that
donor/recipient size ratio plays a dominant role in cardiac
growth. However, another challenging issue may be con-
sidered: does growth occur in those transplanted adult
hearts? These are evidently mismatched hearts when im-
planted into children. What could be the mechanism of
shrinkage in size within months to 1 year after their im-
plantation? These hearts, which have been denervated and
subjected to a barrage of immunosuppressants, have al-
ready gone beyond their potential for cellular hyperplasia.
We have chest x-ray films of these patients showing
a large (adult) heart occupying such a small chest cavity
(Figure 4, A), but over time, they have reduced in size,
and eventually conform (Figure 4, B) to the BSA of the
recipient. It is indeed a provocative issue, and we are con-
cerned to look for possible explanations as to what cellu-
lar mechanisms could be responsible. Presently, on the
basis of our data at hand and the existing, albeit scant,
literature, we may only postulate that there must be
some existing molecular signal pathways directing this in-
teresting response. It remains unresolved what mecha-
nisms govern the proportional cardiac shrinkage of an
adult heart transplanted into a small chest cavity that
then eventually enlarges its dimensions over time in rela-
tion to the bodily growth of its recipient. This is probably
a result of time-dependent genetic factors or extrinsicery c January 2012
FIGURE 4. A, Chest x-ray film of a child who received an adult heart. B, Chest x-ray film of the same child 30 days after transplantation.
Delmo Walter et al Cardiothoracic Transplantationhemodynamic demands. We have only the numbers (di-
mensions and Z-scores) to prove it, but we would not
be able to provide the underlying mechanisms. At pres-
ent, we may only surmise that the shrinkage in trans-
planted adult hearts within a certain period of time
followed by conforming to the somatic growth of the re-
cipient is a physiologic adaptation to the pressure and
volume demands of the growing body.T
XSTUDY LIMITATIONS
Our study was not concerned with the effects of immu-
nosuppression, hemodynamic performance, frequency and
severity of acute and chronic rejections, myocardial fibro-
sis, or myocyte damage in correlation with the changes in
cardiac dimensions and size disparity of transplanted
hearts. A study of changes in peak systolic wall stress after
transplant, which is BSA dependent, would be an impor-
tant addition to the existing body of information. These
issues are the subjects of on-going research in our
institution.CONCLUSIONS
This study demonstrates that despite size disparity, im-
munosuppression and denervation, the transplanted heart
undergoes normal growth in diastolic dimensions, volumes,
and myocardial mass over time appropriate for body growth
after cardiac transplantation in infants and children. Ven-
tricular remodeling occurs by a temporally reversible in-
crease in ventricular diameter, volume, and mass within
several weeks after transplantation, the extent of which is
predicted by the physiologic requirements of the developing
child, as demonstrated in the normalization and increase in
dimensions and volumes over time.
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Dr Charles B. Huddleston (St Louis, Mo). Thanks very much
for providing me the manuscript and the slides and illustrations. It
is an excellent presentation and analysis of the data.
We have looked at the same issue in only our infant population.
We selected that infant population only because that would be
a more consistent group and one in which the growth would be
more obvious in terms of what the expectations would be. I think
that you would not necessarily have to analyze the data specifically
when you see a teenager come back for the 15-year follow-up after
having had a transplant as an infant, for the heart must be growing.
However, this study was a very nice objective demonstration of
that.
Using ventricular dimensions is perhaps the most obvious way
to assess the growth of a heart, but there are a number of variables
that could play into the ventricular dimensions—resting heart rate,
episodes of rejection, the presence of hypertension. I wonder
whether using valvular dimensions, such as the mitral and aortic
valve annular diameters, to assess the growth might actually be
a more accurate way to figure this out. Do you have any comments
about that?
Dr Delmo Walter. Thank you very much for your very con-
structive critique. That is certainly an excellent suggestion. We
will look into all cases in which we have sufficiently complete
echo data on mitral valve measurements of those children, which
I am sure we have.
However, in this present study we did not concern ourselves
with the mitral valve or the annular sizes to measure ventricular
growth, although you have a point there. We were more interested
in the growth of the myocardium inasmuch as this is the structure
that is mostly affected in transplantation, especially in cases of re-
jection and immunosuppression. In addition, looking at the mitral
valve annulus as an indicator of ventricular growth is a rational
idea. If we look at these dimensions in the context of an unbal-
anced atrioventricular canal, this is valid and reliable. Perhaps176 The Journal of Thoracic and Cardiovascular Surgwe could apply this dimension in transplanted hearts. But I may
be able to take a look at your suggestion.
Dr Huddleston. Have you actually ever encountered a single
patient in whom you were suspicious that the growth had been in-
adequate, such as someone who is presenting late with restrictive
type of physiology on their follow-up cardiac catheterizations?
Dr Delmo Walter. I cannot recall any particular case in which
we have a restrictive physiology. I am not aware of such where we
had to discuss a heart that did not grow sufficiently, or even under-
went a retransplantation for that reason. In further studies, we will
begin to look into those cases that lie at the borderline margins of
the spectrum, like slow-growing or fast-growing hearts, and see
whether there could be significant specific findings connected
with those. I think this is a special point to consider in the study
of growth of transplanted hearts. What I can recall, Dr Huddleston,
is that we have 5 patients who were 3 standard deviations below
normal at early follow-up but were close to normal range at late
follow-up. This included 3 infants who have shown delayed linear
growth while still receiving steroids and 2 children receiving high-
dose immunosuppressants because of rejection episodes. In these
patients with poor linear growth, cardiac chamber growth occurred
appropriate for BSA.
Dr Huddleston. Finally, there is this dogma, at least in the pe-
diatric heart transplantation field, about taking small hearts, and to
avoid that particularly in the presence of borderline pulmonary hy-
pertension. I am not convinced that that is true, and I wondered
whether you have any thoughts about taking small donors for
some of your patients in light of the existing dogma.
Dr Delmo Walter. Thank you again for pointing out this
dogma. The dogma lies on the inability of a smaller heart to over-
come the pulmonary vascular resistance. It is known that the neo-
natal heart has impaired ability to increase stroke volume in
response to an increased preload, and such an increase would be
essential to provide adequate circulation for a larger recipient.
There are several reports to increase or extend the donor criteria
so that the donor organ is available for anybody who needs it, like
transplanting even small hearts whether the donor/recipient BSA
ratio is more than 1.2 or discrepant. Patients who receive heart
transplants from smaller donors rely on increased heart rate and el-
evated filling pressures to maintain appropriate cardiac output.
Thus, the smaller donor heart has the ability to maintain circulation
in a larger recipient using the maximum reserve over a substantial
period of time and also has the capability to undergo hypertrophy
despite immunosuppression. My senior author, Professor Hetzer,
has reported on 30 patients who received hearts from smaller do-
nors whose weight was up to 32% less than the recipient’s weight.
Of these, 13 patients had a weight difference between 5% and
10%, 10 had a difference between 10% and 20%, 3 had a difference
between 21% and 30%, and 4 had a difference of more than 30%. It
was concluded in this report that the postoperative graft function
was acceptable for those recipients whose body weight did not ex-
ceed the donor’s weight by more than 20%. However, a weight
difference of more than 20% was associated with significant post-
operative graft dysfunction, although only 1 patient had amarkedly
elevated pulmonary vascular resistance. At the outset, the recipient
should not have severe pulmonary hypertension or significantly el-
evated pulmonary vascular resistance, the graft should be healthy,
and the ischemic time should be relatively short, at least less thanery c January 2012
Delmo Walter et al Cardiothoracic Transplantation4 hours. Of course, it is ideal to use the heart from a donor with
an exact donor/recipient BSA ratio match. However, given the
donor shortage, this is probably not achievable. Our data support
the premise that in selected circumstances, smaller hearts do
not adversely affect the early mortality or late outcome. We
believe that it is safe to extend thewidely accepted donor–recipient
weight match criterion to less than 20%. Nowadays, with clear-cut
indication of transplantation, refinement in donor management,
improvements in perioperative management, and improved immu-
nosuppression, this dogma should therefore be nonexistent. I
would like to say that this area of pediatric transplantation is
a minefield when we talk about outcome of size mismatch on
hemodynamics and growth. There are a lot of interesting areas
of research we can really embark on to improve our understanding
of pediatric heart transplantation.
Dr Ali Mumtaz (Norfolk, Va). Can you share with us any par-
ticular technical problems in trying to fit a very large heart into
a very small chest? I noted in your protocol you said that you
would accept a heart 4 times the size. I personally have had expe-
rience only up to a third. Even at that, at 3 times, in a 2-year-old
child, I had to leave the chest open to wait for the swelling from
previous congestive heart failure to go down and then close the
chest. I am curious to see what measures you take to fit the heart
4 times the normal size.
Dr Delmo Walter. We apply the simple technique already
known to all of us. We open both the pleura. When we cannotThe Journal of Thoracic and Caclose the chest, we leave it open until the swelling decreases
and then perform a delayed closure, although this is an instance
we particularly avoid in transplantation. There were 2 or 3 cases
in which we had to open the central fibrous body of the dia-
phragm and allow the heart to hang in the abdominal cavity for
a time. Inasmuch as most of our patients were bridged to trans-
plant with a mechanical circulatory assist device, their hearts
were at the outset enlarged, and therefore their chest cavity as
well, although their body weight or BSAwas much less than their
chest diameter. I would like to clarify a point I have mentioned in
my presentation as well: When I said that it is our institutional
policy to implant a donor heart 4 times larger than the recipient,
I was not talking about the size of the heart; rather, I meant that
the donor weight or BSA is maybe 4 times that of the recipient’s
weight or BSA.
Dr Emile A. Bacha (New York, NY). Can I clarify something?
The heart is 4 times the size or the donor is 4 times the
size? Also, are we talking BSA or weight? When you say 4
times the size, do you mean the donor heart you accept is up
to 4 times the size, dimension, or do you accept 4 times BSA
or 4 times weight?
Dr Delmo Walter. Four times the BSA, not 4 times the size of
the recipient’s heart itself, because that is not possible. The donor
may be 4 times the BSA or weight of the recipient.
Dr Bacha. Right. That is why I am clarifying. Thank you very
much.rdiovascular Surgery c Volume 143, Number 1 177
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